Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Healthcare stocks have jumped, but the easy money has already been made. Now, these companies have to offer strong profit ...

The bullish sentiment is expected to sustain with the VIX reaching a one-month low. Below are some trading ideas for the near ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Ark Invest chief executive Cathie Wood says the most under-appreciated application of artificial intelligence is “healthcare” ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Space company Rocket Lab USA (NASDAQ: RKLB) enjoyed a modest stock price bump in early trading on the Nasdaq Tuesday, rising 3.7% through 10 a.m. ET. Last night Rocket Lab announced it will delay its ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Earnings are painting a mixed picture within the pharmaceutical space Tuesday morning, as Merck (MRK) and Pfizer (PFE) ...

Ironwood Pharmaceuticals, Inc. (IRWD) stock saw a decline, ending the day at $2.1 which represents a decrease of $-0.24 or -10.26% from the prior close of $2.34. The stock opened at $2.24 and touched ...

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.